^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BAT8010
i
Other names: BAT8010, BAT 8010, BAT-8010
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bio-Thera Solutions
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
1m
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
P1/2, N=216, Recruiting, Bio-Thera Solutions | N=108 --> 216
Enrollment change • Combination therapy • Metastases
|
BAT1006 • BAT8010
5ms
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
P1/2, N=108, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting | Trial primary completion date: May 2024 --> Dec 2024
Enrollment open • Trial primary completion date • Combination therapy • Metastases
|
BAT1006 • BAT8010
7ms
An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study (clinicaltrials.gov)
P1/2, N=108, Not yet recruiting, Bio-Thera Solutions
New P1/2 trial • Combination therapy • Metastases
|
BAT1006 • BAT8010
over1year
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients (clinicaltrials.gov)
P1, N=109, Recruiting, Bio-Thera Solutions
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
BAT8010
Share via
